CG Oncology, Inc. CGON 深 沪
已收盘 02-06 16:00:00 美东时间
50.36
+1.160
+2.36%
华盛通- 最 高51.50
- 今 开50.93
- 成交量 84.17万股
- 最 低 49.71
- 昨 收 49.20
- 总市值 40.62亿
- 52周最高 57.88
- 市盈率 静 --
- 换手率 1.04%
- 52周最低 14.80
- 委 比 62.00%
- 总股本 8066.62万
- 历史最高 57.88
- 量 比 0.90
- 振 幅 3.64%
- 历史最低 14.80
- 每 手 1
- 风险率 9.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 奈飞绩后遭13家大行下调目标价；齐昂银行、美国合众银行获多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从9美元升至50美元；韦德布什：维持Ardelyx, Inc."跑赢大市"评级，目标价从16美元升至19美元
01-22 15:09
RBC Capital Maintains Outperform on CG Oncology, Raises Price Target to $73
RBC Capital analyst Leonid Timashev maintains CG Oncology (NASDAQ:CGON) with a Outperform and raises the price target from $61 to $73.
01-21 22:45
美股大行评级 | 潜在上涨空间31.6%！巴克莱上调台积电目标价至450美元；第一地平线全国银行获5家机构上调目标价
今日重点评级关注：Guggenheim：维持MBX Biosciences"买入"评级，目标价从77美元升至88美元；摩根士丹利：维持DraftKings"超配"评级，目标价从50美元升至53美元
01-20 10:26
美股大行评级 | Medline获14家大行首予评级，最高目标价52美元；富国银行上调GOOGL目标价从268美元升至350美元
今日重点评级关注：HC Wainwright & Co.：维持Enlivex Therapeutics"买入"评级，目标价从7美元升至13美元；BTIG：维持Oruka Therapeutics"买入"评级，目标价从63美元升至73美元
01-13 10:18
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers NovaBay Pharmaceuticals (AMEX:NBY) stock rose 36.9% to $12.95 during F...
01-10 01:05
CG Oncology, Rich Sparkle Holdings, Liquidia And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on ...
01-10 00:25
CG Oncology shares are trading higher after the company announced an expedited timeline for the topline data readout now expected in the first half of 2026 for the Phase 3 PIVOT-006 clinical trial comparing adjuvant intravesical cretostimogene grenadenorepvec versus surveillance in patients with intermediate-risk non-muscle invasive bladder cancer.
CG Oncology shares are trading higher after the company announced an expedited ...
01-09 22:18
CG Oncology Announces Expedited Timeline For Topline Data Readout Now Expected In H1 2026 For Phase 3 PIVOT-006 Clinical Trial In IR NMIBC
- PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule- First randomized registrational trial to evaluate an
01-09 21:36
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers SciSparc (NASDAQ:SPRC) shares rose 6.3% to $1.46 during Monday's after...
2025-12-30 05:05
美股大行评级 | 绩后分化！甲骨文遭14家大行集体下调目标价；新思科技、Planet获多家机构上调目标价！
今日重点评级关注：HC Wainwright & Co.：维持Moleculin Biotech"买入"评级，目标价从4美元升至22美元；HC Wainwright & Co.：上调Soluna Holdings评级至"买入"，目标价5美元
2025-12-12 10:24
